U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    PPP2R1A protein phosphatase 2 scaffold subunit Aalpha [ Homo sapiens (human) ]

    Gene ID: 5518, updated on 9-Jun-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype-Phenotype Analysis in Neurodevelopmentally Delayed Patients.

    Novel Variants of PPP2R1A in Catalytic Subunit Binding Domain and Genotype-Phenotype Analysis in Neurodevelopmentally Delayed Patients.
    Qian Y, Jiang Y, Wang J, Li G, Wu B, Zhou Y, Xu X, Wang H., Free PMC Article

    10/6/2023
    PPP2R1A neurodevelopmental disorder is associated with congenital heart defects.

    PPP2R1A neurodevelopmental disorder is associated with congenital heart defects.
    Baker EK, Solivio B, Pode-Shakked B, Cross LA, Sullivan B, Raas-Rothschild A, Chorin O, Barel O, Bar-Yosef O, Husami A, Hopkin RJ, Prada CE, Stottmann RW, Weaver KN.

    10/15/2022
    Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.

    Chk1 Inhibition Ameliorates Alzheimer's Disease Pathogenesis and Cognitive Dysfunction Through CIP2A/PP2A Signaling.
    Hu W, Wang Z, Zhang H, Mahaman YAR, Huang F, Meng D, Zhou Y, Wang S, Jiang N, Xiong J, Westermarck J, Lu Y, Wang J, Wang X, Shentu Y, Liu R., Free PMC Article

    07/2/2022
    Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.

    Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.
    O'Connor CM, Taylor SE, Miller KM, Hurst L, Haanen TJ, Suhan TK, Zawacki KP, Noto FK, Trako J, Mohan A, Sangodkar J, Zamarin D, DiFeo A, Narla G., Free PMC Article

    03/12/2022
    The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction.

    The broad phenotypic spectrum of PPP2R1A-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction.
    Lenaerts L, Reynhout S, Verbinnen I, Laumonnier F, Toutain A, Bonnet-Brilhault F, Hoorne Y, Joss S, Chassevent AK, Smith-Hicks C, Loeys B, Joset P, Steindl K, Rauch A, Mehta SG, Chung WK, Devriendt K, Holder SE, Jewett T, Baldwin LM, Wilson WG, Towner S, Srivastava S, Johnson HF, Daumer-Haas C, Baethmann M, Ruiz A, Gabau E, Jain V, Varghese V, Al-Beshri A, Fulton S, Wechsberg O, Orenstein N, Prescott K, Childs AM, Faivre L, Moutton S, Sullivan JA, Shashi V, Koudijs SM, Heijligers M, Kivuva E, McTague A, Male A, van Ierland Y, Plecko B, Maystadt I, Hamid R, Hannig VL, Houge G, Janssens V., Free PMC Article

    07/10/2021
    Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.

    Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.
    Kauko O, Imanishi SY, Kulesskiy E, Yetukuri L, Laajala TD, Sharma M, Pavic K, Aakula A, Rupp C, Jumppanen M, Haapaniemi P, Ruan L, Yadav B, Suni V, Varila T, Corthals GL, Reimand J, Wennerberg K, Aittokallio T, Westermarck J., Free PMC Article

    12/12/2020
    R183W mutant of PPP2R1A, the gene encoding the PP2A Aalpha scaffolding subunit, failed to suppress tumor growth in vivo through activation of the MAPK pathway in RAS-mutant transformed cells. Cells expressing R183W were less sensitive to MEK inhibitors. Results demonstrate that the R183W mutation in PPP2R1A potentiates oncogenic signaling and reduces drug sensitivity of RAS-mutant cells to MEK inhibitors.

    Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
    O'Connor CM, Leonard D, Wiredja D, Avelar RA, Wang Z, Schlatzer D, Bryson B, Tokala E, Taylor SE, Upadhyay A, Sangodkar J, Gingras AC, Westermarck J, Xu W, DiFeo A, Brautigan DL, Haider S, Jackson M, Narla G., Free PMC Article

    06/20/2020
    Association of the rs10406151 C variant with AD risk appears to involve brain PPP2R1A gene expression alterations.

    Association of PPP2R1A with Alzheimer's disease and specific cognitive domains.
    Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J, United Kingdom Brain Expression Consortium, PREVENT-AD research group.

    05/9/2020
    In addition, 6 other cancer-associated genes (BRAF, NRAS, HRAS, ERK1, ERK2 and PTEN) were also analyzed. In total, four somatic mutations were identified in three out of 101 ovarian endometriotic lesions (4%, 4/101), including a KRAS p.G12V, a PPP2R1A p.S256F and two ARID1A nonsense mutations (p.Q403* and p.G1926*); while no mutations were identified in the remaining 7 genes (BRAF, NRAS, HRAS, ERK1, ERK2, PTEN and PIK3CA)

    The presence of KRAS, PPP2R1A and ARID1A mutations in 101 Chinese samples with ovarian endometriosis.
    Zou Y, Zhou JY, Guo JB, Wang LQ, Luo Y, Zhang ZY, Liu FY, Tan J, Wang F, Huang OP.

    02/23/2019
    PP2A controls mitotic exit through EG5 dephosphorylation.

    Protein Phosphatase 2A (PP2A) Regulates EG5 to Control Mitotic Progression.
    Liu Y, Zhang Z, Liang H, Zhao X, Liang L, Wang G, Yang J, Jin Y, McNutt MA, Yin Y., Free PMC Article

    12/22/2018
    RAB9 competes with the catalytic subunit PPP2CA in binding to PPP2R1A. This competitive association has an important role in controlling the PP2A catalytic activity.

    A subset of RAB proteins modulates PP2A phosphatase activity.
    Sacco F, Mattioni A, Boldt K, Panni S, Santonico E, Castagnoli L, Ueffing M, Cesareni G., Free PMC Article

    07/21/2018
    Total PP2A activity and PPP2R1A-associated PP2Ac activity were significantly increased in cells overexpressing PPP2R1A-WT. In addition, overexpression of PPP2R1A-WT increased cell proliferation in vitro and tumor growth in vivo

    Patient derived mutation W257G of PPP2R1A enhances cancer cell migration through SRC-JNK-c-Jun pathway.
    Jeong AL, Han S, Lee S, Su Park J, Lu Y, Yu S, Li J, Chun KH, Mills GB, Yang Y., Free PMC Article

    05/5/2018
    PPP2R1A mutations occur in a subset of gastrointestinal stromal tumors and are associated with a high malignant potential that leads to decreased disease-free survival and overall survival

    Clinicopathological effects of protein phosphatase 2, regulatory subunit A, alpha mutations in gastrointestinal stromal tumors.
    Toda-Ishii M, Akaike K, Suehara Y, Mukaihara K, Kubota D, Kohsaka S, Okubo T, Mitani K, Mogushi K, Takagi T, Kaneko K, Yao T, Saito T.

    01/13/2018
    Results demonstrated that the promotive effect of eEF-2K on glycolysis resulted from the kinase-mediated restriction of synthesis of the protein phosphatase 2A-A (PP2A-A).

    eEF-2 kinase is a critical regulator of Warburg effect through controlling PP2A-A synthesis.
    Cheng Y, Ren X, Yuan Y, Shan Y, Li L, Chen X, Zhang L, Takahashi Y, Yang JW, Han B, Liao J, Li Y, Harvey H, Ryazanov A, Robertson GP, Wan G, Liu D, Chen AF, Tao Y, Yang JM.

    09/16/2017
    PPP2R1A mutation is associated with endometrial carcinoma progression and abdominopelvic metastasis.

    The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis.
    Gibson WJ, Hoivik EA, Halle MK, Taylor-Weiner A, Cherniack AD, Berg A, Holst F, Zack TI, Werner HM, Staby KM, Rosenberg M, Stefansson IM, Kusonmano K, Chevalier A, Mauland KK, Trovik J, Krakstad C, Giannakis M, Hodis E, Woie K, Bjorge L, Vintermyr OK, Wala JA, Lawrence MS, Getz G, Carter SL, Beroukhim R, Salvesen HB., Free PMC Article

    09/9/2017
    PPP2R1A mutations affect PP2A function and oncogenic signaling, illuminating the genetic basis for serous EC development.

    Recurrent PPP2R1A Mutations in Uterine Cancer Act through a Dominant-Negative Mechanism to Promote Malignant Cell Growth.
    Haesen D, Abbasi Asbagh L, Derua R, Hubert A, Schrauwen S, Hoorne Y, Amant F, Waelkens E, Sablina A, Janssens V.

    08/5/2017
    PR65A phosphorylation regulates PP2A complex signaling.

    PR65A phosphorylation regulates PP2A complex signaling.
    Kotlo K, Xing Y, Lather S, Grillon JM, Johnson K, Skidgel RA, Solaro RJ, Danziger RS., Free PMC Article

    11/8/2014
    Our results suggest that IH-induced ROS generation increases PP2A activation and subsequently downregulates ERK1/2 activation, which results in inhibition of PC12 cell proliferation through G0/G1 phase arrest and NGF-induced neuronal differentiation.

    Intermittent hypoxia-induced protein phosphatase 2A activation reduces PC12 cell proliferation and differentiation.
    Chen TI, Chiu HW, Pan YC, Hsu ST, Lin JH, Yang KT., Free PMC Article

    09/13/2014
    The two functional variants in PPP2R1A and PPP2R5E and their combinations are associated with lung cancer risk in the Chinese.

    Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese.
    Yang R, Yang L, Qiu F, Zhang L, Wang H, Yang X, Deng J, Fang W, Zhou Y, Lu J., Free PMC Article

    08/9/2014
    Partial unfolding of PR65/A impacts catalysis by altering the proximity of bound catalytic subunit and substrate.

    Complex energy landscape of a giant repeat protein.
    Tsytlonok M, Craig PO, Sivertsson E, Serquera D, Perrett S, Best RB, Wolynes PG, Itzhaki LS., Free PMC Article

    06/28/2014
    For PPP2R1A, a heterozygous, somatic mutation (c.771G>T, p.W257C) was identified in 1 out of 37 patients (2.7%) with primary ovarian endometrioid carcinoma.

    Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.
    Wang F, Zou Y, Liu FY, Yu XH, Huang H, Zhang N, Qi YY, Liu RF, Liu XY, Chen J, Huang OP, He M.

    11/16/2013
    gene transcription of PPP2R1A regulated by the polymorphism and methylation in the promoter region

    Role of a novel functional variant in the PPP2R1A promoter on the regulation of PP2A-Aalpha and the risk of hepatocellular carcinoma.
    Chen HF, Mai JR, Wan JX, Gao YF, Lin LN, Wang SZ, Chen YX, Zhang CZ, Zhang YJ, Xia B, Liao K, Lin YC, Lin ZN., Free PMC Article

    10/19/2013
    This study indicates that the PPP2R1A mutation occurs at a lower frequency compared to other gynecological malignancies, irrespective of the histological subtype

    PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M, Nakayama K, Rahman MT, Nakayama N, Katagiri H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Otsuki Y, Nakayama S, Miyazaki K.

    06/1/2013
    the frequent mutation of PPP2R1A in the serous type of uterine cancer, a low frequency of mutation in endometrioid endometrial cancer and absence of mutation in uterine carcinosarcoma.

    PPP2R1A mutations are common in the serous type of endometrial cancer.
    Nagendra DC, Burke J 3rd, Maxwell GL, Risinger JI.

    12/8/2012
    Our findings suggest that functional genetic variants in the proximal promoter of the PP2A-Aalpha gene and their haplotypes are critical in the regulation of transcriptional activation.

    Identification and functional analyses of polymorphism haplotypes of protein phosphatase 2A-Aα gene promoter.
    Lin YC, Chen HF, Lin LN, Luo J, Li W, Zhang SJ, Li XJ, Hu YM, Chen YX, Chen W, Lin ZN.

    02/11/2012
    firstprevious page of 2 nextlast